Fairooz F. Kabbinavar

37.5k total citations · 7 hit papers
175 papers, 21.8k citations indexed

About

Fairooz F. Kabbinavar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Fairooz F. Kabbinavar has authored 175 papers receiving a total of 21.8k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Pulmonary and Respiratory Medicine, 114 papers in Oncology and 53 papers in Molecular Biology. Recurrent topics in Fairooz F. Kabbinavar's work include Colorectal Cancer Treatments and Studies (59 papers), Renal cell carcinoma treatment (52 papers) and Cancer Treatment and Pharmacology (50 papers). Fairooz F. Kabbinavar is often cited by papers focused on Colorectal Cancer Treatments and Studies (59 papers), Renal cell carcinoma treatment (52 papers) and Cancer Treatment and Pharmacology (50 papers). Fairooz F. Kabbinavar collaborates with scholars based in United States, France and Germany. Fairooz F. Kabbinavar's co-authors include Herbert I. Hurwitz, William Novotny, Louis Fehrenbacher, Eric Holmgren, Jordan Berlin, John D. Hainsworth, W. Heim, Thomas H. Cartwright, Robert W. Ross and Ari David Baron and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Fairooz F. Kabbinavar

172 papers receiving 21.2k citations

Hit Papers

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin... 2002 2026 2010 2018 2004 2004 2002 2007 2005 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
    2004 8.4k citations Herbert I. Hurwitz, William Novotny et al. profile →
  2. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
    2004 1.5k citations William Novotny, Fairooz F. Kabbinavar et al. Journal of Clinical Oncology profile →
  3. Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
    2002 1.3k citations Fairooz F. Kabbinavar, Herbert I. Hurwitz et al. Journal of Clinical Oncology profile →
  4. Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
    2007 725 citations Frank A. Scappaticci, Fairooz F. Kabbinavar et al. profile →
  5. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
    2005 709 citations Fairooz F. Kabbinavar, Joseph J. Schulz et al. Journal of Clinical Oncology profile →
  6. Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
    2005 550 citations Herbert I. Hurwitz, John D. Hainsworth et al. Journal of Clinical Oncology profile →
  7. Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer
    2005 522 citations Fairooz F. Kabbinavar, R. Mass et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fairooz F. Kabbinavar United States 54 12.9k 8.8k 7.8k 4.1k 3.4k 175 21.8k
William Novotny United States 38 12.5k 1.0× 5.7k 0.6× 8.0k 1.0× 3.8k 0.9× 3.0k 0.9× 110 22.6k
Jordan Berlin United States 60 15.3k 1.2× 6.3k 0.7× 6.6k 0.8× 5.0k 1.2× 2.8k 0.8× 357 22.9k
Allan T. van Oosterom Belgium 32 9.3k 0.7× 10.1k 1.2× 4.5k 0.6× 2.8k 0.7× 1.9k 0.6× 89 21.9k
Eric Holmgren United States 24 8.7k 0.7× 4.4k 0.5× 4.8k 0.6× 2.5k 0.6× 2.3k 0.7× 46 14.1k
J. Wanders Netherlands 38 11.1k 0.9× 7.9k 0.9× 4.2k 0.5× 2.8k 0.7× 1.9k 0.6× 132 19.6k
Patrick Therasse Belgium 23 10.9k 0.8× 8.6k 1.0× 3.6k 0.5× 3.8k 0.9× 2.0k 0.6× 36 20.5k
Brian Schwartz United States 47 5.2k 0.4× 5.8k 0.7× 7.7k 1.0× 3.3k 0.8× 2.3k 0.7× 143 14.4k
Jacek Jassem Poland 59 11.4k 0.9× 8.0k 0.9× 4.8k 0.6× 3.9k 0.9× 719 0.2× 523 19.9k
Yoon‐Koo Kang South Korea 69 12.3k 0.9× 13.6k 1.6× 5.2k 0.7× 3.0k 0.7× 4.2k 1.2× 550 26.2k
Patrick Schöffski Belgium 68 9.6k 0.7× 9.5k 1.1× 4.8k 0.6× 2.2k 0.5× 779 0.2× 510 19.4k

Countries citing papers authored by Fairooz F. Kabbinavar

Since Specialization
Citations

This map shows the geographic impact of Fairooz F. Kabbinavar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fairooz F. Kabbinavar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fairooz F. Kabbinavar more than expected).

Fields of papers citing papers by Fairooz F. Kabbinavar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fairooz F. Kabbinavar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fairooz F. Kabbinavar. The network helps show where Fairooz F. Kabbinavar may publish in the future.

Co-authorship network of co-authors of Fairooz F. Kabbinavar

This figure shows the co-authorship network connecting the top 25 collaborators of Fairooz F. Kabbinavar. A scholar is included among the top collaborators of Fairooz F. Kabbinavar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fairooz F. Kabbinavar. Fairooz F. Kabbinavar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahn, Daniel H., Afsaneh Barzi, Maya Ridinger, et al.. (2024). Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical Cancer Research. 30(10). 2039–2047. 20 indexed citations
2.
Ahn, Daniel H., Maya Ridinger, Timothy Lewis Cannon, et al.. (2024). Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Journal of Clinical Oncology. 43(7). 840–851. 11 indexed citations
3.
Franko, Jan, Jun Yin, Richard Adams, et al.. (2022). Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. European Journal of Cancer. 174. 142–152. 3 indexed citations
4.
5.
Saad, Everardo D., Dirkje W. Sommeijer, Qian Shi, et al.. (2014). Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. Journal of Clinical Oncology. 32(15_suppl). 3578–3578. 3 indexed citations
6.
Sommeijer, Dirkje W., Qian Shi, Katrin Marie Sjoquist, et al.. (2013). PROGNOSTIC VALUE OF EARLY OBJECTIVE TUMOR RESPONSE (EOTR) TO FIRST LINE SYSTEMIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS OF RANDOMIZED TRIALS FROM THE ARCAD DATABASE. Asia-Pacific Journal of Clinical Oncology. 9. 76–76. 2 indexed citations
7.
Klatte, Tobias, Nils Kroeger, Edward N. Rampersaud, et al.. (2012). Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer. 118(23). 5777–5782. 38 indexed citations
8.
Kozloff, Mark, Jordan Berlin, Patrick J. Flynn, et al.. (2010). Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology. 78(5-6). 329–339. 94 indexed citations
9.
Klatte, Tobias, Jonathan Said, David B. Seligson, et al.. (2010). Pathological, Immunohistochemical and Cytogenetic Features of Papillary Renal Cell Carcinoma With Clear Cell Features. The Journal of Urology. 185(1). 30–36. 37 indexed citations
10.
Klatte, Tobias, Priya Rao, Michela de Martino, et al.. (2009). Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 27(5). 746–753. 151 indexed citations
11.
Kabbinavar, Fairooz F., Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, & Oliver Rosen. (2008). Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials. Journal of Clinical Oncology. 27(2). 199–205. 135 indexed citations
12.
Shuch, Brian, Tobias Klatte, Stephen B. Riggs, et al.. (2008). Performance status and cytoreductive nephrectomy. Cancer. 113(6). 1324–1331. 45 indexed citations
13.
Klatte, Tobias, Jean‐Jacques Patard, Michela de Martino, et al.. (2008). Tumor Size Does Not Predict Risk of Metastatic Disease or Prognosis of Small Renal Cell Carcinomas. The Journal of Urology. 179(5). 1719–1726. 117 indexed citations
14.
Klatte, Tobias, Michela de Martino, Jonathan Said, et al.. (2008). GENDER SPECIFIC CYTOGENETIC SIGNATURES CAN DISTINGUISH BETWEEN ONCOCYTOMA AND CHROMOPHOBE RENAL CELL CARCINOMA. The Journal of Urology. 179(4S). 168–169. 1 indexed citations
15.
Kabbinavar, Fairooz F., Joseph J. Schulz, Michael McCleod, et al.. (2005). Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 23(16). 3697–3705. 709 indexed citations breakdown →
16.
Hurwitz, Herbert I. & Fairooz F. Kabbinavar. (2005). Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer. Oncology. 69(Suppl. 3). 17–24. 53 indexed citations
17.
18.
Scappaticci, Frank A., L. Fehrenbacher, Thomas H. Cartwright, et al.. (2004). Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery. Journal of Clinical Oncology. 22(14_suppl). 3530–3530. 2 indexed citations
19.
Cloughesy, Timothy F., Emese Filka, John G. Kuhn, et al.. (2003). Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 97(S9). 2381–2386. 88 indexed citations
20.
Strawn, Laurie M., et al.. (2000). Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.. PubMed. 6(7). 2931–40. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Novotny Breakdown of academic impact, for papers by Jordan Berlin Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by Eric Holmgren Breakdown of academic impact, for papers by J. Wanders Breakdown of academic impact, for papers by Patrick Therasse Breakdown of academic impact, for papers by Brian Schwartz Breakdown of academic impact, for papers by Jacek Jassem Breakdown of academic impact, for papers by Yoon‐Koo Kang Breakdown of academic impact, for papers by Patrick Schöffski
Rankless by CCL
2026